12.09
21-二月-25 15:45:00
15 分钟延时
股票
-0.08
-0.66%
今日范围
11.70 - 12.51
ISIN
N/A
来源
NASDAQ
Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease
07 2月 2025 07:00:00 条件 Nasdaq GlobeNewswire